)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
Helius Medical Technologies (HSDT) investor relations material
Helius Medical Technologies Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary18 Aug, 2025
Executive summary
Revenue for Q2 2025 was $43K, down 76% year-over-year, with a net loss of $9.8M compared to $1.6M in Q2 2024, driven by lower sales and a $6.0M loss from derivative warrant liability changes.
Cash and cash equivalents increased to $6.1M as of June 30, 2025, following a $9.1M equity offering and $1.3M private placement, but the company continues to face substantial doubt about its ability to continue as a going concern.
Two reverse stock splits were executed in Q2 and Q3 2025 to regain Nasdaq compliance, and the company is now in compliance with all listing requirements.
The company is pursuing reimbursement for its PoNS device, with several major healthcare payers approving claims in 2025, and is advancing a pivotal stroke study with FDA submission expected in Q3 2025.
Financial highlights
Q2 2025 revenue was $43K, down from $182K in Q2 2024; six-month revenue was $92K, down from $317K year-over-year.
Net loss for Q2 2025 was $9.8M, compared to $1.6M in Q2 2024; six-month net loss was $13.7M, up from $4.1M year-over-year.
Gross loss for Q2 2025 was $53K, compared to gross profit of $64K in Q2 2024; six-month gross loss was $125K versus $76K profit year-over-year.
Operating expenses for Q2 2025 were $3.3M, flat year-over-year; six-month operating expenses rose to $7.2M from $6.8M.
Cash used in operations for the first half of 2025 was $6.3M; net cash provided by financing activities was $11.3M.
Outlook and guidance
Management expects continued operating losses and negative cash flow until revenue growth supports the cost structure; current cash is expected to fund operations into Q2 2026.
Additional capital will be required to fund operations and clinical trials beyond Q2 2026; failure to raise capital may force asset sales or cessation of operations.
FDA submission for stroke indication is planned for Q3 2025, with potential authorization by late 2025 or early 2026.
Assess impact of OBBBA on financials.
Explain the stroke study enrollment.
What is the status of Nasdaq compliance?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Helius Medical Technologies earnings date
Q3 202514 Nov, 2025
Next Helius Medical Technologies earnings date
Q3 202514 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
)
Edge19 Sep 2025
American Express: An Empire of Plastic
How history, brand, and structure have steadily built American Express' moat, and why Warren Buffett still calls it a one-of-a-kind business.
Frequently asked questions
Helius Medical Technologies Inc. is a neurotechnology company focused on developing non-invasive treatments for neurological conditions. The company’s primary product, the Portable Neuromodulation Stimulator (PoNS), is designed to help improve balance and gait in patients with neurological diseases or trauma, such as multiple sclerosis and traumatic brain injury. The PoNS® device stimulates the brain through the tongue, promoting neuroplasticity and aiding in physical rehabilitation. Helius Medical Technologies aims to offer innovative therapeutic solutions to enhance the quality of life for individuals with neurological impairments. The company is headquartered in Newtown, Pennsylvania, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage